Omeros Corporation Common Stock OMER
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-14T01:13:18.566Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-14T00:49:09.630825841Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-14T01:13:18.158316+00:00
Omeros Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.95 | 149.3% | 16.5% | |||
| 25Δ | 20.52 | 151.9% | 20.9% | 15.45 | 150.0% | 14.6% |
| 30Δ | 19.90 | 153.7% | 18.1% | 15.93 | 150.7% | 12.8% |
| 35Δ | 19.40 | 158.7% | 16.3% | 16.40 | 154.3% | 11.5% |
| 40Δ | 18.89 | 162.8% | 14.4% | 16.86 | 158.5% | 10.2% |
| 45Δ | 18.37 | 164.2% | 12.5% | 17.28 | 151.6% | 8.6% |
| 50Δ | 17.86 | 167.6% | 10.9% | 17.68 | 139.9% | 7.0% |
| 55Δ | 17.36 | 175.9% | 9.7% | 18.09 | 130.4% | 5.5% |
| 60Δ | 16.82 | 187.2% | 8.7% | 18.51 | 129.7% | 4.6% |
| 65Δ | 16.21 | 206.2% | 8.0% | 18.93 | 128.9% | 3.8% |
| 70Δ | 15.65 | 202.3% | 6.5% | 19.47 | 130.9% | 3.1% |
| 75Δ | 15.12 | 186.9% | 4.6% | 20.06 | 133.9% | 2.4% |
| 80Δ | 13.82 | 252.7% | 4.8% | 20.95 | 142.8% | 1.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.95
- IV
- 149.3%
- B/E move
- 16.5%
25Δ
- Pseudo strike
- 20.52
- IV
- 151.9%
- B/E move
- 20.9%
- Pseudo strike
- 15.45
- IV
- 150.0%
- B/E move
- 14.6%
30Δ
- Pseudo strike
- 19.90
- IV
- 153.7%
- B/E move
- 18.1%
- Pseudo strike
- 15.93
- IV
- 150.7%
- B/E move
- 12.8%
35Δ
- Pseudo strike
- 19.40
- IV
- 158.7%
- B/E move
- 16.3%
- Pseudo strike
- 16.40
- IV
- 154.3%
- B/E move
- 11.5%
40Δ
- Pseudo strike
- 18.89
- IV
- 162.8%
- B/E move
- 14.4%
- Pseudo strike
- 16.86
- IV
- 158.5%
- B/E move
- 10.2%
45Δ
- Pseudo strike
- 18.37
- IV
- 164.2%
- B/E move
- 12.5%
- Pseudo strike
- 17.28
- IV
- 151.6%
- B/E move
- 8.6%
50Δ
- Pseudo strike
- 17.86
- IV
- 167.6%
- B/E move
- 10.9%
- Pseudo strike
- 17.68
- IV
- 139.9%
- B/E move
- 7.0%
55Δ
- Pseudo strike
- 17.36
- IV
- 175.9%
- B/E move
- 9.7%
- Pseudo strike
- 18.09
- IV
- 130.4%
- B/E move
- 5.5%
60Δ
- Pseudo strike
- 16.82
- IV
- 187.2%
- B/E move
- 8.7%
- Pseudo strike
- 18.51
- IV
- 129.7%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 16.21
- IV
- 206.2%
- B/E move
- 8.0%
- Pseudo strike
- 18.93
- IV
- 128.9%
- B/E move
- 3.8%
70Δ
- Pseudo strike
- 15.65
- IV
- 202.3%
- B/E move
- 6.5%
- Pseudo strike
- 19.47
- IV
- 130.9%
- B/E move
- 3.1%
75Δ
- Pseudo strike
- 15.12
- IV
- 186.9%
- B/E move
- 4.6%
- Pseudo strike
- 20.06
- IV
- 133.9%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 13.82
- IV
- 252.7%
- B/E move
- 4.8%
- Pseudo strike
- 20.95
- IV
- 142.8%
- B/E move
- 1.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 75.99% | |
| 71.20% | |
| 71.84% | |
| 73.29% | |
| 71.39% | |
| 70.58% | |
| 71.56% | |
| 70.08% | |
| 73.71% | |
| 72.78% |
Biotechnology
ONC
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The…
More →ORIC
Description unavailable
More →ORKA
Description unavailable
More →ORMP
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or…
More →OTLK
Description unavailable
More →OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is…
More →